Lung Cancer

The FDA has approved pembrolizumab with platinum-containing chemotherapy for patients with resectable non–small cell lung cancer, in both the neoadjuvant and adjuvant setting.

The FDA has approved encorafenib plus binimetinib to treat adults with metastatic non-small cell lung cancer with a BRAF V600E mutation.

The approval of FoundationOne CDx as a companion diagnostic for selpercatinib seeks to broaden access to therapies for patients with RET fusion–positive solid tumors.

Takeda has announced that they will be voluntarily withdrawing mobocertinib for patients with EGFR exon 20 insertion mutation-positive non–small cell lung cancer.

The FDA Oncologic Drugs Advisory Committee voted 10-to-2 that findings from the phase 3 CodeBreaK 200 trial cannot be reliably interpreted.

Patients with EGFR-mutated non–small cell lung cancer had a median event-free survival of 30.8 months in the durvalumab arm and 19.6 months in the placebo arm.

The benmelstobart combination reduced the risk of death by 39% vs placebo plus chemotherapy in patients with extensive-stage small cell lung cancer.

The pathological complete response among patients who received durvalumab plus chemotherapy was 17.2% vs 4.3% in the placebo plus chemotherapy arm.

Findings from the PACIFIC-R trial showed that patients with EGFR-mutated non-small cell lung cancer experienced shorter progression-free survival with durvalumab than patients with EGFR-wildtype disease.

The confirmed objective response rate with repotrectinib was 79% among tyrosine kinase inhibitor (TKI)-naïve patients and 38% among TKI-pretreated patients.

The median progression-free survival was 25.5 months with osimertinib plus chemotherapy and 16.7 months with osimertinib alone.

The objective response rate with sacituzumab govitecan plus pembrolizumab was 56%.

Patrimumab deruxtecan garnered a 29.8% overall response rate in pretreated patients with EGFR-mutated non–small cell lung cancer.

TTFields therapy, when given in addition to standard systemic therapy, improved overall survival in patients with metastatic non–small cell lung cancer.

Adagrasib elicited a 1-year overall survival rate of 52.8% and 2-year rate of 31.3%.

The median progression-free survival with iruplinalkib was 27.70 months vs 14.62 months with crizotinib.

Oncology nurses can help patients with metastatic lung cancer find meaning in their experiences and potentially help them cope more effectively with their diagnosis.

The FDA has granted regular approval to pralsetinib as a treatment for adults with metastatic RET fusion-positive non-small cell lung cancer.

Patients with recurrent or metastatic non–small cell lung cancer with EGFR exon 20 insertions achieved a confirmed objective response rate of 38.4% with zipalertinib.

Overall survival data from the phase 3 ADUARA trial has further supported the use of osimertinib to treat EGFR-mutant non–small cell lung cancer in the adjuvant setting.

As evidence begins to mount supporting the efficacy of antibody-drug conjugates (ADCs), it is important that clinicians increase their knowledge of ADCs to improve the delivery of these agents.

The investigator-assessed progression-free survival was 9.0 months with sugemalimab plus chemotherapy arm vs 4.9 months with placebo plus chemotherapy.

Patients with EGFR-mutated non–small cell lung cancer and MET positivity may derive greater benefit from amivantamab plus lazertinib than patients who are MET-negative.

Lazertinib reduced the risk of progression by 55% in patients with EGFR-mutated advanced non–small cell lung cancer compared with gefitinib.

Findings from the phase 1b cohort of the KRYSTAL-1 trial underscore the intracranial permeation of the KRAS G12C inhibitor adagrasib for patients with non–small cell lung cancer with untreated central nervous system metastases.

The FDA has launched a priority review of repotrectinib based on data from the phase 1/2 TRIDENT-trial.

Frontline chemoimmunotherapy was associated with improved median overall survival, compared with chemotherapy alone, in patients with advanced non–small cell lung cancer.

Novel strategies for patient education can help to build trust in and decrease the fear of lung cancer screening among patients.

Numerical, but not statistically significant, improvements in survival were observed in patients with TKI-resistant, EGFR-mutated, metastatic nonsquamous non–small cell lung cancer who received pembrolizumab to pemetrexed and platinum-based chemotherapy.

Adjuvant osimertinib reduced the risk of death by 51% compared with placebo for patients with EGFR-mutated, stage IB, II, or IIIA non–small cell lung cancer.